Regulating Gut Microbiome: Therapeutic Strategy for Rheumatoid Arthritis During Pregnancy and Lactation
- PMID: 33343364
- PMCID: PMC7748111
- DOI: 10.3389/fphar.2020.594042
Regulating Gut Microbiome: Therapeutic Strategy for Rheumatoid Arthritis During Pregnancy and Lactation
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial inflammation and bone destruction. Microbial infection is considered to be the most important inducement of RA. The pregnancy planning of women in childbearing age is seriously affected by the disease activity of RA. Gut microbiome, related to immunity and inflammatory response of the host. At present, emerging evidence suggested there are significant differences in the diversity and abundance of gut microbiome during pregnancy and lactation, which may be associated with the fluctuation of RA disease activity. Based on these research foundations, we pioneer the idea of regulating gut microbiome for the treatment of RA during pregnancy and lactation. In this review, we mainly introduce the potential treatment strategies for controlling the disease activity of RA based on gut microbiome during pregnancy and lactation. Besides, we also briefly generalize the effects of conventional anti-rheumatic drugs on gut microbiome, the effects of metabolic changes during pregnancy on gut microbiome, alteration of gut microbiome during pregnancy and lactation, and the effects of anti-rheumatic drugs commonly used during pregnancy and lactation on gut microbiome. These will provide a clear knowledge framework for researchers in immune-related diseases during pregnancy. Regulating gut microbiome may be a potential and effective treatment to control the disease activity of RA during pregnancy and lactation.
Keywords: gut microbiome; lactation; pregnancy; rheumatoid arthritis; treatment.
Copyright © 2020 Yao, Cai, Fei, Ren, Wang, Luan, Chen and Zheng.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
The oral and gut microbiome in rheumatoid arthritis patients: a systematic review.Rheumatology (Oxford). 2021 Mar 2;60(3):1054-1066. doi: 10.1093/rheumatology/keaa835. Rheumatology (Oxford). 2021. PMID: 33450018
-
Data-driven multiple-level analysis of gut-microbiome-immune-joint interactions in rheumatoid arthritis.BMC Genomics. 2019 Feb 11;20(1):124. doi: 10.1186/s12864-019-5510-y. BMC Genomics. 2019. PMID: 30744546 Free PMC article.
-
Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation.Int J Rheum Dis. 2016 Sep;19(9):834-43. doi: 10.1111/1756-185X.12860. Epub 2016 Apr 29. Int J Rheum Dis. 2016. PMID: 27125255 Review.
-
Understanding the roles of the microbiome in autoimmune rheumatic diseases.Rheumatol Immunol Res. 2023 Dec 19;4(4):177-187. doi: 10.2478/rir-2023-0027. eCollection 2023 Dec. Rheumatol Immunol Res. 2023. PMID: 38125641 Free PMC article.
-
Troublesome friends within us: the role of gut microbiota on rheumatoid arthritis etiopathogenesis and its clinical and therapeutic relevance.Clin Exp Med. 2021 Feb;21(1):1-13. doi: 10.1007/s10238-020-00647-y. Epub 2020 Jul 25. Clin Exp Med. 2021. PMID: 32712721 Review.
Cited by
-
The Macrophage-Osteoclast Axis in Osteoimmunity and Osteo-Related Diseases.Front Immunol. 2021 Mar 31;12:664871. doi: 10.3389/fimmu.2021.664871. eCollection 2021. Front Immunol. 2021. PMID: 33868316 Free PMC article. Review.
-
The Role of Methyl Canthin-6-one-2-carboxylate in Targeting the NLRP3 Inflammasome in Rheumatoid Arthritis Treatment.Curr Issues Mol Biol. 2025 Apr 7;47(4):254. doi: 10.3390/cimb47040254. Curr Issues Mol Biol. 2025. PMID: 40699653 Free PMC article. Review.
-
The Effects of Tocotrienol on Gut Microbiota: A Scoping Review.Life (Basel). 2023 Sep 7;13(9):1882. doi: 10.3390/life13091882. Life (Basel). 2023. PMID: 37763286 Free PMC article.
-
Impact of Posttranslational Modification in Pathogenesis of Rheumatoid Arthritis: Focusing on Citrullination, Carbamylation, and Acetylation.Int J Mol Sci. 2021 Sep 30;22(19):10576. doi: 10.3390/ijms221910576. Int J Mol Sci. 2021. PMID: 34638916 Free PMC article. Review.
References
-
- Angelakis E., Million M., Kankoe S., Lagier J. C., Armougom F., Giorgi R., et al. (2014). Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment. Antimicrob. Agents Chemother. 58 (6), 3342–3347. 10.1128/AAC.02437-14 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources